tofa

TOFA (MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA).

TOFA-Plasmalogen (compound 1), a derivative of glyceraldehyde, exhibits ferroptosis-inducing properties. This compound promotes lipid peroxidation in cell membranes, leading to cytotoxic effects with an inhibition concentration (IC 50 = 32.87 μM).

Tofacitinib (Tasocitinib) is a Janus kinase inhibitor that inhibits JAK3/2/1 (IC50=1/20/112 nM) and is orally active. Tofacitinib is used for the treatment of moderate to severe rheumatoid arthritis.

Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).

(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.

(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.

(3S,4R)-Tofacitinib is a less active enantiomer of Tofacitinib, which is a JAK3 inhibitor (IC50: 1 nM).

Etofamide, an antimicrobial agent, exhibits an IC50 of 5.96 mg/L against amoebae.

Tofacitinib metabolite-1, a derivative of Tofacitinib, which is a JAK inhibitor, is employed in studies focused on the pharmacokinetics and metabolism of tofacitinib[1][2].

Fantofarone (SR 33557) is a highly potent antagonist of Calcium Channel.

Tofacitinib maleate, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib maleate modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib maleate inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively.

Tofacitinib HCl, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib HCl modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib HCl inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively.

Tofacitinib Prodrug-1 is an effective and oral active prodrug to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib Prodrug-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib Prodrug-1 is a potential drug candidate for the treatment of ulcerative colitis .

Tofacitinib-13C3 is a carbon-13 labeled variant of Tofacitinib. Tofacitinib (T6321) acts as a JAK3/2/1 inhibitor, exhibiting IC50 values of 1 nM, 20 nM, and 112 nM, respectively.

Tofacitinib-D3 Citrate is a deuterated compound of Tofacitinib Citrate. Tofacitinib Citrate (T2398) has a CAS number of 540737-29-9. Tofacitinib citrate is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).

Tofacitinib-[13C3, 15N] (Standard) is a reference standard of Tofacitinib-[13C3, 15N] intended for quantitative analysis, quality control, and related biochemical research applications.

Tofacitinib Impurity T (3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide) is a pharmaceutical intermediate utilized in the synthesis of various active compounds.

Tofacitinib impurity 32 is an impurity of Tofacitinib.

Tofacitinib impurity 3 is an impurity associated with Tofacitinib.

Tofacitinib impurity 2 is an impurity of Tofacitinib.

Quoromycin is a novel antivirulence agent against Vibrio vulnificus, inhibiting the quorum-sensing signaling pathway by controlling the DNA-binding affinity of SmcR and thus effectively alleviating the virulence of V. vulnificus in vitro and in vivo.

BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.